biotech firms
Apr 13, 2017
Cancer, diabetes and eczema on list; AbbVie’s Humira; Teva weighs $2B; Fresenius in buyout talks
Cancer, diabetes and eczema star in 2017 top-launch list Launch prognostications are getting more attention than ever as they come out with “Drugs to Watch” list, and the highlights of different drugs shows what might work this year. By 2021, some of the drugs in the list are expected to bring in $16 billion, shared...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
